55
Participants
Start Date
June 30, 2013
Primary Completion Date
December 31, 2015
Study Completion Date
February 20, 2018
brentuximab vedotin
1.8 mg/kg every 3 weeks by intravenous (IV) infusion
bendamustine
90 mg/m2 on Days 1 and 2 of 3-week cycles
Columbia University Medical Center, New York
Saint Francis Hospital / Bon Secours, Greenville
University of Alabama at Birmingham, Birmingham
Case Western Reserve University / University Hospitals Case Medical Center, Cleveland
Jewish Hospital, The, Cincinnati
Mayo Clinic Minnesota, Rochester
Charles A. Sammons Cancer Center / Baylor University Medical Center, Dallas
Colorado Blood Cancer Institute, Denver
Oncology Institute of Hope & Innovation, The, Whittier
Pacific Hematology Oncology Associates, San Francisco
Stanford Cancer Center, Stanford
Dana Farber Cancer Institute, Boston
University of Nebraska Medical Center, Omaha
Seagen Inc.
INDUSTRY